CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis
| العنوان: | CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis |
|---|---|
| المؤلفون: | Sara Llufriu, Albert Saiz, Luisa M. Villar, Eva Borràs, Antonio J. Sánchez López, Manuel Comabella, Sergio Martínez-Yélamos, Eduard Sabidó, J.A. García-Merino, Rucsanda Pinteac, Lucienne Costa-Frossard, Yolanda Blanco, Xavier Montalban, Jaume Sastre-Garriga, Angela Vidal-Jordana, Nicolás Fissolo |
| المساهمون: | Institut Català de la Salut, [Comabella M, Sastre-Garriga J, Pinteac R, Fissolo N, Vidal-Jordana A, Montalban X] Unitat de Neuroimmunologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Borras E] Proteomics Unit, Universitat Pompeu Fabra, Barcelona. [Villar LM] Departments of Neurology and Immunology, Hospital Universitario Ramon y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid. [Saiz A] Service of Neurology, Hospital Clinic and Institut d’Investigacions Biomèdiques August Pi Sunyer, University of Barcelona. [Martínez-Yélamos S] Department of Neurology, Bellvitge University Hospital, Barcelona, Vall d'Hebron Barcelona Hospital Campus |
| المصدر: | Dipòsit Digital de la UB Universidad de Barcelona Scientia Neurology® Neuroimmunology & Neuroinflammation article-version (Version of Record) 3 |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health), 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Adult, Male, Oncology, medicine.medical_specialty, Enzymes and Coenzymes::Enzymes::Hydrolases::Glycoside Hydrolases::Chitinases [CHEMICALS AND DRUGS], enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple::esclerosis múltiple crónica progresiva [ENFERMEDADES], Esclerosi múltiple, Article, Multiple sclerosis, Glicosidases, Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis::Multiple Sclerosis, Chronic Progressive [DISEASES], Internal medicine, Cathepsin L1, medicine, Humans, Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Progression [DISEASES], enzimas y coenzimas::enzimas::hidrolasas::glicósido hidrolasas::quitinasas [COMPUESTOS QUÍMICOS Y DROGAS], Shotgun proteomics, CSF albumin, biology, business.industry, Chitinases, Biochemical markers, Patient Acuity, Area under the curve, Middle Aged, Multiple Sclerosis, Chronic Progressive, Prognosis, Esclerosi múltiple - Prognosi, afecciones patológicas, signos y síntomas::procesos patológicos::atributos de la enfermedad::progresión de la enfermedad [ENFERMEDADES], Clinical trial, Neurology, Estudi de casos, Chitinase, Cohort, Marcadors bioquímics, Disease Progression, biology.protein, Biomarker (medicine), Female, Neurology (clinical), Case studies, business, Biomarkers, Follow-Up Studies |
| الوصف: | ObjectiveThis study aimed to identify long-term prognostic protein biomarkers associated with disease progression in patients with progressive multiple sclerosis (MS).MethodsCSF samples were collected from a discovery cohort of 28 patients with progressive MS who participated in a clinical trial with interferon beta. Patients were classified into high and low disability progression phenotypes according to numeric progression rates (NPR) and step-based progression rates (SPR) after a mean follow-up time of 12 years. Protein abundance was measured by shotgun proteomics. Selected proteins from the discovery cohort were quantified by parallel reaction monitoring in CSF samples from an independent validation cohort of 41 patients with progressive MS classified also into high and low disability progression phenotypes after a mean follow-up time of 7 years.ResultsOf 2,548 CSF proteins identified in the discovery cohort, 10 were selected for validation based on their association with long-term disability progression: SPATS2-like protein, chitinase 3–like 2 (CHI3L2), plasma serine protease inhibitor, metallothionein-3, phospholipase D4, beta-hexosaminidase, neurexophilin-1, adipocyte enhancer-binding protein 1, cathepsin L1, and lipopolysaccharide-binding protein. Only CHI3L2 was validated, and patients with high disability progression exhibited significantly higher CSF protein levels compared with patients with low disability progression (p = 0.03 for NPR and p = 0.02 for SPR). CHI3L2 levels showed good performance to discriminate between high and low disability progression in patients with progressive MS (area under the curve 0.73; sensitivity 90% and specificity 63%).ConclusionsAlthough further confirmatory studies are needed, we propose CSF CHI3L2 as a prognostic protein biomarker associated with long-term disability progression in patients with progressive MS.Classification of EvidenceThis study provides Class II evidence that high CSF CHI3L2 levels identified higher disability progression in patients with progressive MS. |
| وصف الملف: | application/pdf |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99a8c1143873c1eb36072ddb0b4dda07Test http://hdl.handle.net/2445/181334Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....99a8c1143873c1eb36072ddb0b4dda07 |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |